DNA RNA and Cells

22 Nov 2022 OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C’s Potential as an Effective Treatment for Hair Loss
22 Nov 2022 Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
21 Nov 2022 Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
21 Nov 2022 Medera receives FDA clearance for a first-in-human gene therapy trial for heart failure with preserved ejection fraction
18 Nov 2022 Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
18 Nov 2022 Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
18 Nov 2022 Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
17 Nov 2022 Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
14 Nov 2022 4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
14 Nov 2022 PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
12 Nov 2022 Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis
12 Nov 2022 Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
12 Nov 2022 Carisma Therapeutics Announces Clinical & Pre-Clinical Updates
12 Nov 2022 Triumvira Immunologics Announces Updated Data from Ongoing TACTIC 2 Trial of TAC01-HER2 in Patients with HER2 Positive Solid Tumors
12 Nov 2022 Nutcracker Therapeutics Reports Strong Anti-Tumor Responses of Lead mRNA Immunotherapy in Preclinical Data Presented at SITC Annual Meeting 2022
11 Nov 2022 Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
11 Nov 2022 CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102
10 Nov 2022 Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
10 Nov 2022 IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022
10 Nov 2022 Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting
10 Nov 2022 Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10 Nov 2022 Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
10 Nov 2022 Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
10 Nov 2022 CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10 Nov 2022 KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up